Nektar Therapeutics Presents Pre-Clinical Data Combining NKTR 214 With Checkpoint Blockade

By: via Benzinga
Nektar Therapeutics (NASDAQ: NKTR) disclosed fresh preclinical data for its investigational immune-stimulatory cytokine therapy, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.